Addex Therapeutics annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
Addex Therapeutics Free Cash Flow (FCF) History (ADXN)
Addex Therapeutics reported −CHF5.4M in free cash flow for fiscal 2024, an increase of CHF2.6M from the previous fiscal year, with a free cash flow margin of −1310.80%.
View full Addex Therapeutics company overviewAddex Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −CHF5.4M | CHF2.6M | — | −1310.80% |
| 2023 | 2023-12-31 | −CHF8.0M | CHF8.4M | — | −494.64% |
| 2022 | 2022-12-31 | −CHF16.4M | −CHF1.7M | — | −1137.59% |
| 2021 | 2021-12-31 | −CHF14.7M | −CHF2.5M | — | −467.34% |
| 2020 | 2020-12-31 | −CHF12.2M | −CHF2.7M | — | −315.52% |
| 2019 | 2019-12-31 | −CHF9.5M | −CHF11.3M | — | −335.63% |
| 2018 | 2018-12-31 | CHF1.7M | CHF3.9M | — | +26.00% |
| 2017 | 2017-12-31 | −CHF2.1M | — | — | −428.19% |
Addex Therapeutics quarterly free cash flow
Q2.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | −CHF419,842 | — | — | −1154.20% |
Addex Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −CHF9.5M to −CHF5.4M, a net increase of CHF4.1M. Addex Therapeutics's latest reported quarter, Q2 2025, generated −CHF419,842 in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Addex Therapeutics source filings ↗Community posts
Addex reports limited cash as half-year loss reaches CHF3.46 million
Addex Therapeutics ($ADXN) reported a first-half net loss of CHF3.46 million, compared with CHF3.31 million a year earlier. Its operating loss narrowed to CHF1.13 million, but the share of losses from associates increased to CHF2.33 million ...
